- Home
- DXLG vs CTSO Comparison
DXLG vs CTSO Comparison
Compare DXLG & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXLG
- CTSO
- Stock Information
- Founded
- DXLG 1976
- CTSO 1997
- Country
- DXLG United States
- CTSO United States
- Employees
- DXLG N/A
- CTSO N/A
- Industry
- DXLG Clothing/Shoe/Accessory Stores
- CTSO Medical/Dental Instruments
- Sector
- DXLG Consumer Discretionary
- CTSO Health Care
- Exchange
- DXLG Nasdaq
- CTSO Nasdaq
- Market Cap
- DXLG 55.4M
- CTSO 57.6M
- IPO Year
- DXLG 1987
- CTSO N/A
- Fundamental
- Price
- DXLG $1.27
- CTSO $1.16
- Analyst Decision
- DXLG Strong Buy
- CTSO Buy
- Analyst Count
- DXLG 1
- CTSO 2
- Target Price
- DXLG $2.50
- CTSO $5.50
- AVG Volume (30 Days)
- DXLG 230.8K
- CTSO 324.9K
- Earning Date
- DXLG 08-27-2025
- CTSO 08-07-2025
- Dividend Yield
- DXLG N/A
- CTSO N/A
- EPS Growth
- DXLG N/A
- CTSO N/A
- EPS
- DXLG N/A
- CTSO N/A
- Revenue
- DXLG $457,059,000.00
- CTSO $36,107,520.00
- Revenue This Year
- DXLG N/A
- CTSO $11.15
- Revenue Next Year
- DXLG $3.56
- CTSO $21.39
- P/E Ratio
- DXLG N/A
- CTSO N/A
- Revenue Growth
- DXLG N/A
- CTSO 20.18
- 52 Week Low
- DXLG $0.90
- CTSO $0.71
- 52 Week High
- DXLG $3.12
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- DXLG 49.04
- CTSO 60.19
- Support Level
- DXLG $1.24
- CTSO $1.03
- Resistance Level
- DXLG $1.32
- CTSO $1.22
- Average True Range (ATR)
- DXLG 0.08
- CTSO 0.09
- MACD
- DXLG -0.01
- CTSO 0.03
- Stochastic Oscillator
- DXLG 25.93
- CTSO 86.61
About DXLG Destination XL Group Inc.
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store, and Direct business.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.